Prosecution Insights
Last updated: November 15, 2026
Application No. 17/917,958

ALL-IN-ONE AAV VECTORS FOR TREATING CORONAVIRUS-INDUCED DISEASES

Non-Final OA §112
Filed
Oct 10, 2022
Priority
Apr 08, 2020 — provisional 63/006,996 +1 more
Examiner
HUDSON, AMY ROSE
Art Unit
1636
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Elisabeth Zeisberg
OA Round
3 (Non-Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
86%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1096 granted / 1466 resolved
+14.8% vs TC avg
Moderate +12% lift
Without
With
+11.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
102 currently pending
Career history
1542
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/8/26 has been entered. Drawings The drawings filed on 7/8/26 are objected to because color photographs and color drawings are not accepted in utility applications unless a petition filed under 37 CFR 1.84(a)(2) is granted. Any such petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification: The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2). Allowable Subject Matter Claims 1, 8, 10, 12-19, 22, 25, 43, and 44 are allowed. Claim Objections Claims 26, 30-33, and 35 are objected to because of the following informalities: Claims 26, 33, and 35 appear to inadvertently recite “an disease” instead of “a disease”. Appropriate correction is required. Claims 30-32 are objected to because they depend from claim 26. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 26, 30-33, 35, 45, and 46 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. THIS IS A NEW MATTER REJECTION. Claims 26, 33, and 35 have been amended to require “the human-associated virus caused disease or syndrome is a respiratory illness or a disease of the myocardium”, which is not disclosed in the specification. Although the specification discloses that an AAV vector can be delivered to the lungs or myocardium, the specification does not disclose that the human-associated virus caused disease or syndrome is a respiratory illness or a disease of the myocardium”. Claims 30-32, 45, and 46 are rejected because they depend from a rejected base claim. MPEP §2163.06 notes: If new matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112, first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981). MPEP §2163.02 teaches that: Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed...If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application. A review of the specification does not reveal support for where the claim amendments are found. Should applicant disagree, applicants are encouraged to point out with particularity by page and line number where such support might exist for each claim limitation added in the amended claims filed on 7/8/26. There is no support for this claim limitation in the claimed priority documents. Therefore, the effective filing date of the instant claims is considered, for purposes of prior art, to be 10/10/22, which is the filing date of the instant application. Claims 26, 30-33, and 35 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims recite wherein the human-associated virus caused disease or syndrome is an infection caused by a coronavirus, wherein the coronavirus is selected from MERS-CoV, SARS-CoV, SARS-CoV-2, and “derivatives thereof”. The specification does not adequately describe the genus of derivatives of MERS-CoV, SARS-CoV, SARS-CoV-2 that function as claimed. The specification does not adequately describe the structure required for the function. The specification discloses MERS-CoV, SARS-CoV, SARS-CoV-2, which are species that are not representative of the entire claimed genus. Without further description of the required structure for the function, one would not be able to readily recognize which diseases or syndromes are caused by MERS-CoV, SARS-CoV, SARS-CoV-2, and “derivatives thereof”. The specification does not adequately describe the genus of human-associated diseases or syndromes that are caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof that is a respiratory illness or a disease of the myocardium. Without further description of the genus, one would not be able to readily envision which human-associated diseases or syndromes are caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, and derivatives thereof that is a respiratory illness or a disease of the myocardium. Claims 26, 33, and 35 have been amended to require “the human-associated virus caused disease or syndrome is a respiratory illness or an disease of the myocardium”, which is a genus that has not been adequately described in the specification. The specification does not disclose any representative species of respiratory illnesses or diseases of the myocardium that are caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof. Response to Arguments Applicant argues that the claims, as presently amended, eliminates the "at least 50% genomic sequence similarity" language that served as the basis for the Examiner's written description rejection. The amended claims no longer claim a broad genus of derivatives defined by an open-ended similarity threshold. Instead, the amended claims recite a structurally and functionally defined limitation: "...wherein the human-associated virus caused disease or syndrome is an infection caused by a coronavirus, wherein the coronavirus is selected from MERS-CoV, SARS-CoV, SARS-CoV-2, and derivatives thereof, wherein the guide RNA binds to a target site that is a sequence conserved between the respective genomes of SARS- CoV-2, MERS-CoV and SARS-CoV.” Contrary to applicant’s arguments, the claims recite MERS-CoV, SARS-CoV, SARS-CoV-2, and “derivatives thereof”, wherein the specification does not adequately describe derivatives of MERS-CoV, SARS-CoV, SARS-CoV-2 and does not adequately describe the specific genus of diseases or syndromes that are caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or derivatives of each. Applicant argues that: The "conserved sequence" limitation thus provides a clear, objective, and well- understood structural definition of the target site that any skilled artisan can readily identify using standard bioinformatics tools (e.g., CLUSTAL Omega, BLAST alignment). The specification further discloses a sequence alignment of the complete genomes of SARS-CoV- 2, SARS-CoV, and MERS-CoV and identifies the five conserved genomic regions (ORFlab, S, E, M, and N) as the structural basis for guide RNA design. See e.g., paragraphs [0050], [0077], [0167] and Figure 4. Moreover, thirty-nine (39) guide RNA sequences targeting these conserved regions are fully characterized in the instant specification (e.g., Table 1, SEQ ID NOs 1-39), spanning all five conserved genomic regions. The base claim is directed to specific gRNAs, so the language regarding binding to a conserved site fails to further limit the base claim and does not appear to add any meaningful limitation in addition to the requirement of specific spacer sequence in the base claim. Applicant argues that: With respect to the claimed "derivatives thereof' aspect, the amended claims do not define derivatives solely by a similarity threshold. Rather, derivatives are implicitly constrained by the functional limitation that the guide RNA target site must be a sequence conserved between SARS-CoV-2, MERS-CoV, and SARS-CoV. Any derivative coronavirus that contains a guide RNA target site conserved between these three named viruses is, by definition, within the scope of the amended claims. Therefore, this is not an open-ended genus. Instead, it is a genus defined by a shared structural feature, the conserved target sequence, that the specification identifies, characterizes, and demonstrates to be functional. Any derivative of SARS-CoV-2, MERS-CoV, or SARS-CoV with any length of sequence in common between the three genomes has not been adequately described in the specification. The claims encompass derivatives with any level of variance from SARS-CoV-2, MERS-CoV, or SARS-CoV as long as there is any sequence in common between the three genomes, a genus that has not been adequately described in the specification. The specification does not adequately describe which diseases or syndromes are caused by such. It is noted that applicant is arguing the limitations of the claims regarding the gRNA binding site with regards to the coronavirus to be treated although these are separate limitations. The claims are directed to treatment of any human-associated virus caused disease or syndrome that is an infection caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof. The specification does not adequately describe the genus of diseases or syndromes that are infections caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof. The gRNA is required to bind to any target site that is a sequence conserved between MERS-CoV, SARS-CoV, and SARS-CoV-2, which is not limiting to the actual disease state caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative of any of these. The target site for the gRNA does not change the claimed scope of diseases and in fact the target site is already defined in the base claim by recitation of the spacer sequences. Claims 26 and 30-32 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating SARS-CoV-2 via delivery of AAV comprising specific gRNAs, does not reasonably provide enablement for a method of treating any human-associated disease or syndrome caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, and derivatives thereof that are respiratory illnesses or diseases of the myocardium. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Factors to be considered in a determination of lack of enablement include, but are not limited to: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) The instant claims are directed to a method of treating any human-associated disease or syndrome caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof that are respiratory illnesses or diseases of the myocardium, , wherein the guide RNA binds at even a single nucleotide to any target site of any length within a sequence conserved between the respective genomes. The specification does not draw an adequate nexus between delivery of the instantly recited composition and the treatment of any human-associated disease or syndrome that is a respiratory illness or disease of the myocardium caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or derivatives thereof. The specification demonstrates reduction of SARS-CoV2 titer in vitro after delivery of AAV comprising specific gRNAs. Reduction of SARS-CoV2 is not commensurate in scope with a method of treating any human-associated disease or syndrome that is a respiratory illness or disease of the myocardium caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or derivatives thereof. With regards to delivery, Luther et al. (EXPERT OPINION ON DRUG DELIVERY, 2018, VOL. 15, NO. 9, 905–913) teach: Introduction of the CRISPR/Cas9 machinery into a higher-level organism is a challenge. Delivery of the editing machinery into the cells, the cytosol and then the nucleus is the first obstacle that must be considered when evaluating strategies. There are certain shortcomings which severely hinder applicability, especially when considering the potential for translatability (page 910). The scope of the claims in view of the specification as filed together do not reconcile the unpredictability in the art to enable one of skill in the art to make and/or use the claimed invention, namely a broad method of treating any human-associated disease or syndrome that is a respiratory illness or disease of the myocardium caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or derivatives thereof via broad systemic delivery of AAV comprising guide RNA as claimed encompassing in vivo effects. MPEP 2164.01 Any analysis of whether a particular claim is supported by the disclosure in an application requires a determination of whether that disclosure, when filed, contained sufficient information regarding the subject matter of the claims as to enable one skilled in the pertinent art to make and use the claimed invention. Also, MPEP 2164.01(a) A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993). Given the teachings of the specification as discussed above, one skilled in the art could not predict a priori whether introduction of the instantly recited composition in vivo by the broadly disclosed methodologies of the instantly claimed invention, would result in successful treatment of any human-associated disease or syndrome that is a respiratory illness or disease of the myocardium caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or derivatives thereof. To practice the claimed invention, one of skill in the art would have to de novo determine; the stability of the molecule in vivo, delivery of the molecule to the whole organism, specificity to the target tissue in vivo, dosage and toxicity in vivo, and entry of the molecule into the cell in vivo and the effective action therein. Without further guidance, one of skill in the art would have to practice a substantial amount of trial and error experimentation, an amount considered undue and not routine, to practice the instantly claimed invention. A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation (see MPEP 2164.01(a)). Response to Arguments Applicant argues that with respect to the breadth of the claims, as amended, the claims are directed to a specific, structurally-defined genus of coronaviruses united by shared conserved genomic regions. The claims are not directed to all RNA viruses, all coronaviruses, but only to those where the guide RNA target site is a sequence conserved between the three named species. Applicant submits that this is a scientifically well-defined group. With respect to the nature of the invention, the claimed invention employs CRISPR-Cas13, a well-established gene-editing platform with documented activity in mammalian cells. The claims are directed to a method of treating any human-associated disease or syndrome caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof that are respiratory illnesses or diseases of the myocardium. It is noted that applicant is arguing the limitations of the claims regarding the gRNA binding site with regards to the coronavirus to be treated although these are separate limitations. The claims are directed to treatment of any human-associated virus caused disease or syndrome that is an infection caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof. The specification does enable treatment of the instant genus of diseases or syndromes that are infections caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof. The gRNA is required to bind to any target site that is a sequence conserved between MERS-CoV, SARS-CoV, and SARS-CoV-2, wherein the base claim already requires specific spacer sequences, which is not limiting to the actual disease state caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative of any of these. The target site for the gRNA does not change the claimed scope of diseases and the specification does not draw an adequate nexus between broad AAV systemic delivery of any gRNA that targets any possible site conserved between MERS-CoV, SARS-CoV, and SARS-CoV-2, and the predictable outcome of treatment of any human-associated virus caused disease or syndrome that is an infection caused by MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof. Applicant argues that regarding the state of the art, the use of CRISPR systems for antiviral applications and the use of AAV vectors for respiratory gene delivery were both established in the art at the time of filing. Concerning the level of one of ordinary skill, a person of ordinary skill in this field would be an expert in molecular biology, virology, and CRISPR systems, possessing a detailed understanding of coronavirus biology, AAV vector production, and guide RNA design methodologies. With respect to the level of predictability, the conserved genomic regions identified by the inventors (ORFlab, S, E, M, N) are structural hallmarks of human-pathogenic beta coronaviruses (see, e.g., [0077]: "SARS-CoV-2 has been reported to contain 10 different proteins ORF1ab, S, ORF3a, E, M, ORF6, ORF7a, ORF8, N, ORF10." ). IT is noted that the claims are not limited to any specific genomic target region. Contrary to applicant’s arguments regarding AAV vectors, Hadi et al. (Cells 2024, 13, 1794, 1-24), for example, teach: While the CRISPR/Cas13d system shows great promise as a tool for developing antiviral strategies against RNA viruses, including SARS-CoV-2, several limitations need to be addressed before this technology can be widely adopted in medical practice. The most pressing challenge is the lack of a reliable and safe method for delivering CRISPR components into human respiratory tract cells. Although AAV appears to be a feasible option due to the small size of the Cas13d enzyme, the possibility of an adaptive immune response against AAV remains a concern (page 17). Hadi et al. teach: AAV-mediated delivery is considered a viable option for in vivo applications, particularly for gene therapy (Figure 7). However, the use of AAV is not without challenges, including potential immune responses against the viral vector, which may limit its effectiveness in some cases (page 16). Therefore, a person of ordinary skill in the art would recognize substantial uncertainty/challenges in utilizing AAV carrying gRNAs for COVID treatment and would not be able to predictably practice the instant claim breadth without undue experimentation. Tan et al. (Genes 2025, 16, 875, 1-20) teach: Efficiently delivering Cas13 and its associated crRNAs into target cells remains a major obstacle. Viral vectors, such as adeno-associated viruses (AAVs), are commonly used to deliver CRISPR systems but face limitations, including immune responses and limited capacity to deliver large cargo (page 13). Applicant argues: With respect to the amount of direction provided by the inventors, the specification provides exhaustive guidance: three complete guide RNA design methodologies ([0086] et seq.); thirty-nine characterized guide RNA sequences (SEQ ID NOs 1-39; Table 1); five complete AAV vector constructs (SEQ ID NOs 40-44); and detailed protocols for AAV production and transduction in the quantified working Examples. However, these examples of the specification are not enabling for the instant claim breadth. Applicant argues: With respect to the existence of working examples, the specification discloses two complete experimental series in live-virus BSL-3 assays using authentic SARS-CoV-2 (MOI 0.01) in human lung epithelial cells (Calu-3), demonstrating 93-100% reduction in SARS-CoV- 2 infectivity at 24-48 hours post-infection across multiple guide RNA combinations ([0179] with FIGs. 7A-7B, FIG. 8). Critically, these are not in vitro reporter assays, they are live-virus experiments in the clinically relevant primary target cell type (e.g., human respiratory epithelium) under BSL-3 containment, constituting compelling proof-of-concept of therapeutic efficacy. The Examiner's characterization of the working examples as merely demonstrating "reduction of SARS-CoV-2 titer in vitro" (Action, page 7) seems to understate the significance and translational relevance of these experiments. As set forth in the rejection, the experimental data of the specification is not enabling for the instant claim breadth, the treatment of any human-associated disease or syndrome caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof that are respiratory illnesses or diseases of the myocardium, via delivery of any gRNA that binds to any target site in any sequence conserved between MERS-CoV, SARS-CoV, SARS-CoV-2. The specification does not demonstrate that targeting any possible conserved site between the three, wherein no specific target sequence is claimed, would predictably result in treatment of such a broad and undefined breadth of conditions. Applicant argues that regarding the quantity of experimentation needed, a skilled artisan seeking to apply the disclosed system to a derivative coronavirus within the conserved target site limitation would simply need to: (1) perform a standard CLUSTAL Omega or BLAST alignment of the derivative coronavirus genome against the three named species to identify conserved sequences; (2) select a guide RNA from the disclosed library of guides (SEQ ID NOs 1-39) or design a new spacer using the disclosed methodologies according to the invention; (3) clone the spacer into one of the disclosed vector constructs (SEQ ID NOs 40-44); and (4) validate efficacy using standard viral inhibition assays. Applicant submits that these steps can be routine for a person of ordinary skill in the art and does not require undue experimentation. Contrary to applicant’s assertion, determination of delivery of the instant genus of which of the instant gRNAs via an AAV via any mode of delivery would in fact result in the predictable treatment of any human-associated disease or syndrome caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof that are respiratory illnesses or diseases of the myocardium would require undue experimentation. With regards to Luther et al., Luther et al. is relevant as to delivery changes for CRISPR systems, which are known for both Cas9 and Cas13. The Examiner states that a skilled artisan would need to "de novo determine" in vivo stability, biodistribution, tissue specificity, dosage, and toxicity of the claimed composition. See Action on page 9. Applicant respectfully submits that this overstates the experimentation required. The AAV vector platform has been extensively characterized for in vivo delivery to respiratory tissue, including in human clinical trials: the specification cites AAV2-based clinical experience in cystic fibrosis patients (ref. 8: Moss et al., CHEST 2004). Stability, dosage, and toxicity parameters for AAV vectors are well-known in the art and constitute routine characterization, not undue experimentation. Contrary to applicant’s arguments, the undue experimentation has not been overstated and the specification is not enabling for the instant claim breadth. The AAV platform for Cas13d is known to have challenges and the reference cited by applicant is not enabling for the instant claim breadth and is not enabling for the delivery of gRNA and Cas13d from an AAV vector via any means to treat any human-associated disease or syndrome caused by any MERS-CoV, SARS-CoV, SARS-CoV-2, or any derivative thereof that are respiratory illnesses or diseases of the myocardium. As set forth above, Hadi et al. (Cells 2024, 13, 1794, 1-24) teach: While the CRISPR/Cas13d system shows great promise as a tool for developing antiviral strategies against RNA viruses, including SARS-CoV-2, several limitations need to be addressed before this technology can be widely adopted in medical practice. The most pressing challenge is the lack of a reliable and safe method for delivering CRISPR components into human respiratory tract cells. Although AAV appears to be a feasible option due to the small size of the Cas13d enzyme, the possibility of an adaptive immune response against AAV remains a concern (page 17). Hadi et al. teach: AAV-mediated delivery is considered a viable option for in vivo applications, particularly for gene therapy (Figure 7). However, the use of AAV is not without challenges, including potential immune responses against the viral vector, which may limit its effectiveness in some cases (page 16). Therefore, a person of ordinary skill in the art would recognize substantial uncertainty/challenges in utilizing AAV carrying gRNAs for COVID treatment and would not be able to predictably practice the instant claim breadth without undue experimentation. Tan et al. (Genes 2025, 16, 875, 1-20) teach: Efficiently delivering Cas13 and its associated crRNAs into target cells remains a major obstacle. Viral vectors, such as adeno-associated viruses (AAVs), are commonly used to deliver CRISPR systems but face limitations, including immune responses and limited capacity to deliver large cargo (page 13). Applicant argues: The specification also provides detailed in vivo administration methodologies, including intranasal and intratracheal delivery and AAV2 aerosol inhalation. See, e.g., [0037] and [0044]. Applicant is arguing limitations that are not claimed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy R Hudson whose telephone number is (571)272-0755. The examiner can normally be reached M-F 8:00am-6:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil Hammell can be reached at 571-270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMY ROSE HUDSON/Primary Examiner, Art Unit 1636
Read full office action

Prosecution Timeline

Oct 10, 2022
Application Filed
Oct 02, 2025
Non-Final Rejection mailed — §112
Jan 01, 2026
Response Filed
Apr 08, 2026
Final Rejection mailed — §112
Jul 08, 2026
Request for Continued Examination
Jul 09, 2026
Response after Non-Final Action
Sep 23, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790616
NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES
3y 6m to grant Granted Nov 10, 2026
Patent 12751965
DESIGN METHOD FOR OPTIMIZED RIG-I LIGANDS
4y 9m to grant Granted Oct 06, 2026
Patent 12747274
RECOMBINANT VECTOR COMPRISING CODON-OPTIMIZED TIF1# POLYNUCLEOTIDE, AND USE THEREOF
4y 2m to grant Granted Sep 29, 2026
Patent 12740997
OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING
3y 1m to grant Granted Sep 22, 2026
Patent 12735699
COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION
5y 2m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
86%
With Interview (+11.7%)
High
PTA Risk
Based on 1466 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month